Rapid progressive sensorineural hearing damage as the early sign of a hematological illness is often found in patients with Chronic Myeloid Leukemia. A 100-year- old man presented to our outpatient department with 2 hours history of bilateral sudden sensorineural hearing loss (SSNHL). After the hematological, bone marrow and radiological workup, the patient was found to have chronic myelogenous leukemia.

Obstructive Sleep Apnea Syndrome (OSAS) is a chronic disease characterized by repeated airfl ow obstruction in the upper airway. Location of obstructive site is essential for proper surgical planning. Objective: To evaluate the success rate of multiple surgeries, in various combinations, in the treatment of Moderate and Severe OSAS.

Purpose: The hearing loss is the most frequent sensory alteration of the human being, with numerous medical, social, emotional and cultural implications. It is a multicausal pathology and is related to many risk factors. Identify the risk factors for the appearance of hearing loss in the child.

Guillain-Barré syndrome (GBS) is a heterogeneous, relatively uncommon, post-infectious, immune-mediated polyradiculoneuropathy. It is estimated to affect 1.1-1.8/100,000/year in Europe and North America [1].

The aim of this study was to evaluate the expression of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) in patients with primary inverted papilloma (IP), recurrence of IP and carcinoma based on IP. The study was performed on an archived material of the 52 patients that were surgically treated because of the primary IP, recurrent IP and carcinoma that developed on the ground of IP on the Tertiary care University Center in the period of 18 years. The expression of the EGFR and VEGF were measured by an immunohistochemistry method using commercially available antibodies.

There are many types of surgical instrumentation and techniques used to perform adenotonsillectomy. The choice of instrument depends on several factors and the benefits of clinical outcomes must outweigh the costs of newer technologies. Our study seeks to compare the discharge times following inpatient adenotonsillectomy using monopolar electrosurgery vs. radiofrequency ablation. Participants included thirty children aged 2 to 8 years old who underwent adenotonsillectomy via monopolar electrocautery or radiofrequency ablation and were admitted for inpatient observation. Eighteen patients underwent tonsillectomy with monopolar electrocautery and 10 patients underwent tonsillectomy with radiofrequency ablation. There was no intergroup difference in age, sex, weight, and indication for tonsillectomy. Total hospital length of stay and variance to a goal of discharge before 8 AM on postoperative day #1 was measured. Results demonstrated statistically significant difference in mean length of stay (19.6 vs. 22.4 hours, p = 0.037) and variance to discharge time (139.5 vs. 15.6 min, p = 0.032) in favor of the radiofrequency ablation group. In this small number of patients, there was significantly earlier discharge times in children undergoing adenotonsillectomy with radiofrequency ablation when compared to monopolar electrocautery. Further cost analysis in a larger sample could determine potential cost benefits to the institution.

Introduction: The primary aim of this prospective study was to evaluate headache severity before and after surgery in patients with chronic rhinosinusitis without polyps (CRSsNP), chronic rhinosinusitis with polyps (CRSwNP), deviated nasal septum (DNS), and inferior turbinate hypertrophy (ITH). Our secondary aim was to compare the improvement of headache symptoms in these different patient groups.

Rapid progressive sensorineural hearing damage as the early sign of a hematological illness is often found in patients with Chronic Myeloid Leukemia. A 100-year- old man presented to our outpatient department with 2 hours history of bilateral sudden sensorineural hearing loss (SSNHL). After the hematological, bone marrow and radiological workup, the patient was found to have chronic myelogenous leukemia.